Latest Mitochon Pharmaceuticals News & Updates

See the latest news and media coverage for Mitochon Pharmaceuticals. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Mitochon Pharmaceuticals

Clinical-stage biotech developing mitochondria-targeting drugs

mitochonpharma.com
Headquarters
Blue Bell, United States
Founded year
2014
Company type
Private company
Number of employees
4–10

Latest news about Mitochon Pharmaceuticals

Company announcements

  • Mitochon Pharmaceuticals

    Mitochon Pharmaceuticals repurposes DNP for brain treatments

    MP101 and MP201 modulate mitochondria for neuroprotection, mimicking fasting benefits and inducing BDNF for cognition and neural growth.

  • Mitochon Pharmaceuticals

    Mitochon Pharmaceuticals completes promising ALS drug trial

    Early-stage European study with 18 patients over two weeks shows signs of slowing disease progression by stabilizing mitochondria. One patient regained ability to button shirt.

  • Mitochon Pharmaceuticals

    Mitochon completes ALS studies with MP101

    In 2025, they conducted two 14-day European studies showing remarkable CSF biomarkers. They plan a larger 2026 study on sporadic ALS. MP101 reversed paralysis in hSOD1 model.

  • Mitochon Pharmaceuticals

    Mitochon Pharmaceuticals announces DNP preserves motor function in ALS mice

    Micro-doses of DNP delayed disease onset, improved motor coordination, preserved muscle function, and induced functional recovery in hSOD1G93A mice.

Unlock all announcements with a

Media coverage

Track future articles with a

Never miss news about Mitochon Pharmaceuticals

Track Mitochon Pharmaceuticals and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.